New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
09:36 EDTAEGREMA rejection bodes well for Aegerion, says Deutsche Bank
Deutsche Bank said the European Medicines Agency's rejection of the re-examination request for Mipomersen in Homozygous Familial Hypercholesterolemia bodes well for the approval of Aegerion's Lomitapide in Europe. The firm reiterates a Buy rating on Aegerion with a $41 price target.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AEGR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use